Tag:
Advaxis
Latest Headlines
Latest Headlines
Advaxis nets $23M in financing for cancer vaccine development
Advaxis is pushing full steam ahead to test its cancer vaccine candidates in immunotherapy combos, and it just scored another $23 million to help its hopefuls through the clinic.
Advaxis inks pact with Incyte to test cervical cancer vaccine combo
Advaxis, on a partnering spree after joining with Merck and AstraZeneca to test its cancer vaccine candidates in immunotherapy combos, has teamed up with Incyte to trial one of its prospects in cervical cancer.
Advaxis and Incyte pair off amid immuno-oncology's partnering blitz
Advaxis has signed a deal to study its in-development immuno-oncology candidate in tandem with a complementary cancer drug from Incyte, the latest combo trial in a field rife with collaboration.
Advaxis teams up with Merck to test its vaccine in prostate cancer
Just over a month after striking an immunotherapy pact with AstraZeneca, New Jersey biotech Advaxis is back with another Big Pharma agreement. This time, the company will be teaming up with Merck to test its cancer vaccine, ADXS-PSA, in combination with the latter's checkpoint inhibitor pembrolizumab.
Merck and Advaxis forge another no-money-down IO development pact
Almost exactly one year after Daniel O'Connor was named CEO at Advaxis, he celebrated the personal milestone with the latest in a string of deals. Pharma giant Merck stepped up with a no-strings-attached immuno-oncology development pact for pembrolizumab, one of the hot new checkpoint inhibitors promising a groundbreaking new approach to treating a wide variety of cancers.
AstraZeneca inks deal with Advaxis for immunotherapy-vaccine combo trial
AstraZeneca's MedImmune has joined up with immunotherapy maker Advaxis to evaluate the Big Pharma's antibody MEDI4736 in conjunction with the Princeton, NJ-based biotech's lead cancer vaccine in patients with HPV-related cancers.
Advaxis picks inVentiv for cancer immunotherapy trials
Vaccine developer Advaxis is teaming up with CRO inVentiv Health to advance a stable of oncology candidates that work by mounting an immune system attack on cancer tissue.
Vaccine, radiotherapy combo shows hints of prostate cancer efficacy
Radiotherapy is commonly used in the treatment of prostate cancer, and immunotherapy company Advaxis has seen some promising preclinical results when it combined its prostate cancer vaccine, ADXS-PSA (ADXS31-142), with a dose of radiation, in a study published in Cancer Immunology Immunotherapy.
